Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000072.xml
Download PDF
Semin Reprod Med
DOI: 10.1055/s-0045-1810420
DOI: 10.1055/s-0045-1810420
Review Article
Fertility Following Fertility-Sparing Surgery for Borderline Ovarian Tumors
Abstract
Borderline ovarian tumors (BOTs) are commonly diagnosed in women of reproductive age, raising concerns about the impact of surgical management on fertility. This review explores the role of fertility-sparing surgery (FSS) and fertility preservation (FP) strategies in young women diagnosed with BOTs. While FSS carries a slightly higher risk of recurrence compared to bilateral salpingo-oophorectomy, there is growing evidence supporting the safety of FSS, with no adverse effects on 10-year overall survival. In light of this, recent multidisciplinary guidelines recommend FSS for BOT at all stages. A significant proportion of women with BOTs report infertility prior to diagnosis, suggesting a possible pathophysiological link between reduced reproductive fitness and the development of BOT. The potential association between ovarian stimulation (OS) and an increased risk of BOT remains controversial, with current evidence failing to establish a definitive causal link. For women with recurrent stage I BOT and no evidence of peritoneal disease on imaging, OS followed by oocyte retrieval is a viable option before definitive surgery. Notably, a history of BOT does not significantly affect pregnancy outcomes following IVF. FP counseling is essential to tailor treatment plans that address both oncological and reproductive needs in patients undergoing FSS for BOT.
Keywords
borderline ovarian tumor - fertility-sparing surgery - fertility preservation - cryopreservation - counselingPublication History
Article published online:
23 July 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. In: 4th ed. Lyon: International Agency for Research on Cancer 2014 . Accessed July 15, 2025 at: http://VH7QX3XE2P.search.serialssolutions.com/?V=1.0&L=VH7QX3XE2P&S=JCs&C=TC0001705053&T=marc&tab=BOOKS
- 2 Skírnisdóttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 2008; 123 (08) 1897-1901
- 3 Tropé CG, Kaern J, Davidson B. Borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2012; 26 (03) 325-336
- 4 Silverberg SGBD, Bell DA, Kurman RJ. et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol 2004; 35 (08) 910-917
- 5 Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol 2005; 18 (Suppl. 02) S33-S50
- 6 Huang Y, Zhang W, Wang Y. The feasibility of fertility-sparing surgery in treating advanced-stage borderline ovarian tumors: a meta-analysis. Taiwan J Obstet Gynecol 2016; 55 (03) 319-325
- 7 Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Daraï E. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril 2005; 83 (02) 284-290 , quiz 525–526
- 8 Fauvet R, Demblocque E, Morice P, Querleu D, Daraï E. Behavior of serous borderline ovarian tumors with and without micropapillary patterns: results of a French multicenter study. Ann Surg Oncol 2012; 19 (03) 941-947
- 9 Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 2012; 13 (03) e103-e115
- 10 Prat J. Pathology of borderline and invasive cancers. Best Pract Res Clin Obstet Gynaecol 2017; 41: 15-30
- 11 Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J. Diagnosis and treatment of borderline ovarian neoplasms “the state of the art.”. Eur J Gynaecol Oncol 2009; 30 (05) 471-482
- 12 Cosyns S, De Sutter P, Tournaye H, Polyzos NP. Necessity of appendectomy for mucinous borderline ovarian tumors. Systematic review. Arch Gynecol Obstet 2016; 294 (06) 1283-1289
- 13 du Bois A, Ewald-Riegler N, de Gregorio N. et al; Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer 2013; 49 (08) 1905-1914
- 14 Malpica A, Longacre TA. Prognostic indicators in ovarian serous borderline tumours. Pathology 2018; 50 (02) 205-213
- 15 Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 1988; 62 (10) 2212-2222
- 16 Sherman ME, Mink PJ, Curtis R. et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 2004; 100 (05) 1045-1052
- 17 Falcone F, Breda E, Ferrandina G. et al. Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database. Gynecol Oncol 2021; 161 (03) 825-831
- 18 Lokuhetty DWV, Watanabe R. WHO classification: Female genital Tumours. 5th ed. Lyon: International Agency for Research on Cancer (IARC).; 2020
- 19 Cosyns S, Van Moer E, De Quick I, Tournaye H, De Vos M. Reproductive outcomes in women opting for fertility preservation after fertility-sparing surgery for borderline ovarian tumors. Arch Gynecol Obstet 2024; 309 (05) 2143-2152
- 20 Daraï E, Fauvet R, Uzan C, Gouy S, Duvillard P, Morice P. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update 2013; 19 (02) 151-166
- 21 Du Bois A, Trillsch F, Mahner S, Heitz F, Harter P. Management of borderline ovarian tumors. Ann Oncol 2016; 27 (Suppl. 01) i20-i22
- 22 Yinon Y, Beiner ME, Gotlieb WH, Korach Y, Perri T, Ben-Baruch G. Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors. Fertil Steril 2007; 88 (02) 479-484
- 23 Delle Marchette M, Ceppi L, Andreano A. et al. Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery. Eur J Cancer 2019; 111: 61-68
- 24 Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer 2015; 51 (05) 620-631
- 25 Palomba S, Zupi E, Russo T. et al. Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Hum Reprod 2007; 22 (02) 578-585
- 26 Palomba S, Falbo A, Del Negro S. et al. Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up. Hum Reprod 2010; 25 (08) 1966-1972
- 27 Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19 (10) 2658-2664
- 28 Uzan C, Kane A, Rey A, Gouy S, Duvillard P, Morice P. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol 2010; 21 (01) 55-60
- 29 Plett H, Harter P, Ataseven B. et al. Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. Gynecol Oncol 2020; 157 (02) 411-417
- 30 Morice P, Scambia G, Abu-Rustum NR. et al. Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE. Lancet Oncol 2024; 25 (11) e602-e610
- 31 Koskas M, Uzan C, Gouy S. et al. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol 2011; 18 (01) 40-48
- 32 Westermann T, Karabeg E, Heitz F. et al. Role of fertility-sparing surgery and further prognostic factors in borderline tumors of the ovary. Int J Gynecol Cancer 2024; 34 (06) 898-905
- 33 Chevrot A, Pouget N, Bats AS. et al. Fertility and prognosis of borderline ovarian tumor after conservative management: results of the multicentric OPTIBOT study by the GINECO & TMRG group. Gynecol Oncol 2020; 157 (01) 29-35
- 34 Khiat S, Provansal M, Bottin P, Saias-Magnan J, Metzler-Guillemain C, Courbiere B. Fertility preservation after fertility-sparing surgery in women with borderline ovarian tumours. Eur J Obstet Gynecol Reprod Biol 2020; 253: 65-70
- 35 Gotlieb WH, Flikker S, Davidson B, Korach Y, Kopolovic J, Ben-Baruch G. Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer 1998; 82 (01) 141-146
- 36 Camatte S, Morice P, Pautier P, Atallah D, Duvillard P, Castaigne D. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG 2002; 109 (04) 376-380
- 37 Gouy S, Maria S, Faron M. et al. Results after conservative surgery of stage II/III serous borderline ovarian tumors. Ann Surg Oncol 2021; 28 (07) 3597-3604
- 38 Sobiczewski P, Piatek S, Michalski W. et al. Obstetric outcomes after conservative management of ovarian borderline tumors in women of reproductive age: a single center experience. Eur J Obstet Gynecol Reprod Biol 2022; 269: 126-131
- 39 Practice Committee of the American Society for Reproductive Medicine, Society of Reproductive Surgeons. Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery. Fertil Steril 2007; 88 (01) 21-26
- 40 Mangili G, Somigliana E, Giorgione V. et al. Fertility preservation in women with borderline ovarian tumours. Cancer Treat Rev 2016; 49: 13-24
- 41 Lundberg FE, Johansson ALV, Rodriguez-Wallberg K, Gemzell-Danielsson K, Iliadou AN. Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study. Eur J Epidemiol 2019; 34 (11) 1093-1101
- 42 van Leeuwen FE, Klip H, Mooij TM. et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 2011; 26 (12) 3456-3465
- 43 Cusidó M, Fábregas R, Pere BS, Escayola C, Barri PN. Ovulation induction treatment and risk of borderline ovarian tumors. Gynecol Endocrinol 2007; 23 (07) 373-376
- 44 Bjørnholt SM, Kjaer SK, Nielsen TS, Jensen A. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study. Hum Reprod 2015; 30 (01) 222-231
- 45 Basille C, Olivennes F, Le Calvez J. et al. Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours. Hum Reprod 2006; 21 (12) 3241-3245
- 46 Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Fertility drugs and cancer: a guideline. Fertil Steril 2024; 122 (03) 406-420
- 47 Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23 (19) 4347-4353
- 48 Bonardi B, Massarotti C, Bruzzone M. et al. Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: a systematic review and meta-analysis. Front Oncol 2020; 10: 574669
- 49 Lombardi Fäh V, Del Vento F, Intidhar Labidi-Galy S, Undurraga M. Ovarian stimulation with letrozole in nulliparous young women with relapsing early-stage serous borderline ovarian tumors. Gynecol Oncol Rep 2024; 56: 101531
- 50 Beiner ME, Gotlieb WH, Davidson B, Kopolovic J, Ben-Baruch G. Infertility treatment after conservative management of borderline ovarian tumors. Cancer 2001; 92 (02) 320-325
- 51 Fortin A, Morice P, Thoury A, Camatte S, Dhainaut C, Madelenat P. Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study. Fertil Steril 2007; 87 (03) 591-596
- 52 Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org, Practice Committee of the American Society for Reproductive Medicine. Fertility drugs and cancer: a guideline. Fertil Steril 2016; 106 (07) 1617-1626
- 53 Ayhan A, Gultekin M, Taskiran C. et al. Routine appendectomy in epithelial ovarian carcinoma: is it necessary?. Obstet Gynecol 2005; 105 (04) 719-724
- 54 Fasouliotis SJ, Davis O, Schattman G, Spandorfer SD, Kligman I, Rosenwaks Z. Safety and efficacy of infertility treatment after conservative management of borderline ovarian tumors: a preliminary report. Fertil Steril 2004; 82 (03) 568-572
- 55 Johansen G, Dahm-Kähler P, Staf C, Flöter Rådestad A, Rodriguez-Wallberg KA. Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study. Fertil Steril 2021; 115 (01) 157-163
- 56 Li S, Lin H, Xie Y, Jiao X, Qiu Q, Zhang Q. Live births after in vitro fertilization with fertility-sparing surgery for borderline ovarian tumors: a case series and literature review. Gynecol Obstet Invest 2019; 84 (05) 445-454
- 57 Jia SZ, Xiang Y, Yang JJ, Shi JH, Jia CW, Leng JH. Oncofertility outcomes after fertility-sparing treatment of bilateral serous borderline ovarian tumors: results of a large retrospective study. Hum Reprod 2020; 35 (02) 328-339
- 58 Letourneau JM, Ebbel EE, Katz PP. et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 2012; 118 (06) 1710-1717
- 59 Armuand G, Wettergren L, Nilsson J, Rodriguez-Wallberg K, Lampic C. Threatened fertility: a longitudinal study exploring experiences of fertility and having children after cancer treatment. Eur J Cancer Care (Engl) 2018; 27 (02) e12798
- 60 Poulain M, Vandame J, Tran C, Koutchinsky S, Pirtea P, Ayoubi JM. Fertility preservation in borderline ovarian tumor patients and survivors. Horm Mol Biol Clin Investig 2020; 43 (02) 179-186
- 61 Peccatori FA, Azim Jr HA, Orecchia R. et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 06) vi160-vi170
- 62 Kasaven LS, Jones BP, Heath C. et al. Reproductive outcomes from ten years of elective oocyte cryopreservation. Arch Gynecol Obstet 2022; 306 (05) 1753-1760
- 63 Santulli P, Blockeel C, Bourdon M. et al. Fertility preservation in women with benign gynaecological conditions. Hum Reprod Open 2023; 2023 (02) hoad012
- 64 Porcu E, Venturoli S, Damiano G. et al. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online 2008; 17 (02) 265-267
- 65 Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013; 99 (01) 37-43
- 66 Cobo A, Coello A, de Los Santos MJ. et al. Number needed to freeze: cumulative live birth rate after fertility preservation in women with endometriosis. Reprod Biomed Online 2021; 42 (04) 725-732
- 67 Hagen CP, Vestergaard S, Juul A. et al. Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril 2012; 98 (06) 1602-8.e2
- 68 Bourdon M, Raad J, Dahan Y. et al. Endometriosis and ART: a prior history of surgery for OMA is associated with a poor ovarian response to hyperstimulation. PLoS One 2018; 13 (08) e0202399
- 69 Huang JY, Buckett WM, Gilbert L, Tan SL, Chian RC. Retrieval of immature oocytes followed by in vitro maturation and vitrification: a case report on a new strategy of fertility preservation in women with borderline ovarian malignancy. Gynecol Oncol 2007; 105 (02) 542-544
- 70 Prasath EB, Chan ML, Wong WH. et al. First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient. Hum Reprod 2014; 29 (02) 276-278
- 71 Segers I, Mateizel I, Van Moer E. et al. In vitro maturation (IVM) of oocytes recovered from ovariectomy specimens in the laboratory: a promising “ex vivo” method of oocyte cryopreservation resulting in the first report of an ongoing pregnancy in Europe. J Assist Reprod Genet 2015; 32 (08) 1221-1231
- 72 Filippi F, Martinelli F, Somigliana E, Franchi D, Raspagliesi F, Chiappa V. Oocyte cryopreservation in two women with borderline ovarian tumor recurrence. J Assist Reprod Genet 2020; 37 (05) 1213-1216
- 73 Segers I, Bardhi E, Mateizel I. et al. Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes. Hum Reprod 2020; 35 (09) 2026-2036
- 74 Higuchi S, Miyamoto T, Oka K, Kobara H, Shiozawa T. Successful pregnancy using immature oocytes retrieved from resected borderline ovarian tumor: a case report and literature review. Contracept Reprod Med 2024; 9 (01) 24
- 75 Mulder RL, Font-Gonzalez A, Hudson MM. et al; PanCareLIFE Consortium. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2021; 22 (02) e45-e56
- 76 Masciangelo R, Bosisio C, Donnez J, Amorim CA, Dolmans MM. Safety of ovarian tissue transplantation in patients with borderline ovarian tumors. Hum Reprod 2018; 33 (02) 212-219
- 77 Dolmans MM. Safety of ovarian autotransplantation. Blood 2012; 120 (22) 4275-4276
- 78 Fain-Kahn V, Poirot C, Uzan C. et al. Feasibility of ovarian cryopreservation in borderline ovarian tumours. Hum Reprod 2009; 24 (04) 850-855
- 79 Segers I, Mateizel I, Wouters K. et al. Ovarian tissue oocyte-in vitro maturation for fertility preservation. J Vis Exp 2024; (207) 207
- 80 Helpman L, Yaniv A, Beiner ME. et al. Fertility preservation in women with borderline ovarian tumors - how does it impact disease outcome? A cohort study. Acta Obstet Gynecol Scand 2017; 96 (11) 1300-1306